WHO WE ARE
Tetratherix (formerly Trimph) is an Australian biomedical company that has developed TetraMatrix, a novel class of regenerative scaffolds.
TetraMatrix is a water based solution that forms an adhesive hydrogel once administered to the body. The product is fully synthetic, biocompatible and resorbable. TetraMatrix has been clinically tested, demonstrating both safety and efficacy.
Tetratherix has a robust Intellectual Property portfolio including granted patents in the USA and Europe as well as multiple international patent applications.
After 5 years in development at the University of Sydney, Tetratherix was incorporated in 2015. The company’s Sydney based production facility is ISO13485:2016 certified.
Tetratherix is supported by both NSW and Federal government grants. Tetratherix is backed by Ryder Innovation Fund, a venture capital limited partnership specialising in medtech opportunities.
TetraMatrix is an injectable, water based scaffold that can be administered to without the need for invasive surgery.
At body temperature, TetraMatrix instantly forms an adhesive hydrogel to provide a synthetic extracellular matrix to support tissue repair.
TetraMatrix compliments the healing process by providing an optimised environment for cellular ingrowth and regeneration.
TetraMatrix resorbs to the body over time while host cells repair the damaged tissue.
Tetratherix has established its own production faciltiy in Sydney, Alexandria. The company’s clean room production facility is fully equipped to manufacture sterile medical device in commercial scales. The infrastructure and the associated quality management system are ISO13485:2016 certified. The company’s in-house production facility is of a great importance for quality control, protection of technology know-hows, product development and production scalability. In addition, the company’s certified production capability facilitates efficient development and corporate partnership.
TetraMatrix has been assessed in two clinical trials. The company has completed its first in-human trial in Perth, Australia and a pivotal trial is underway. The pilot trial involved the use of TetraMatrix for socket preservation, post tooth extraction. In all patients, the device was successfully administered and there was no need for membrane closure or micro-suturing at the extraction site. In follow-up visits, wound closure was noted at seven days post-extraction and there was no sign of infection or inflammation. Three months post-operation, tissue biopsies were collected for histochemical analysis; the results showed that TetraMatrix was fully resorbed and there were no sign pathological abnormalities. In addition, active bone remodelling was also noted at the site.
Easily injectable, instant gelation,
and no device malfunctions
No infection, inflammation
or pain reported
Wound closure noted
at 7 days post-extraction
Active bone remodelling
in all collected tissue samples
Polymer and peptide bonding
At a molecular level, TetraMatrix is a water based hydrogel comprising of a proprietary patented smart polymer and peptide which are chemically bound to form a uniform structure. Upon injection to the body, TetraMatrix forms an elastic scaffold. The mechanical properties, adhesivity and the resorption rate of TetraMatrix are modifiable to address different clinical indications.
The smart polymer, denoted as PNPHO, was developed and patented by Tetratherix. PNPHO consists of four main building blocks each monomer is required to impart the unique characteristics of the technology;
- N-isopropylacrylamide to impart temperature curing properties to the matrix
- N-acryloxysuccinimide, to be able to bond with peptides to impart the required structural stability to the hydrogel
- Polylactide/2-hydroxy methacrylate to be able to adjust the mechanical properties of the matrix
- Oligo (ethylene glycol) to form a water based matrix
Amine groups of peptides are chemically bound to the succinimide ester units of PNPHO, this process is termed crosslinking. The resorption rate of the final product can be tuned by the degree of crosslinking between PNPHO and a peptide. This allows the formulation of Tetratherix hydrogels with varying physical properties for different clinical applications.
TetraMatrix technology is used to develop pipeline products for multiple clinical indications.
NEWS AND MEDIA
The unique gel can be injected into the body to help regenerate damaged tissue such as bones and cartilage. After only five years of development, this patented university-researched biomedical technology will go to human trials.
An injectable biomaterial that can aid in the regeneration of damaged body tissues such as cartilage, spinal cord and bones will reduce the need for and risks of open surgery. The technology – called Trimph (Temperature-Responsive Modifiable Peptide Hydrogel) – is one of 50 innovations to have snagged a spot in Engineers Australia’s Most Innovative Engineers list.
For more information or product for research purposes, please contact us.
DR ALI FATHI
Directror | Co-founder
Director | Co-founder
PROFESSOR DAVID CURROW
DR DAX CALDER
TetraPharm can be used as a delivery vehicle for a range of active pharmaceuticals and growth factors including vaccines, drugs and bioactive graft. In vitro and in vivo studies show the controlled release of compounds and activity of encapsulated drugs within the TetraPharm carrier technology. The product is currently under development with feasibility trials initially focused on nasal delivery applications.